Medivation , Inc. and Pfizer Inc. announced results from the CONCERT trial, which is a Phase 3 trial that evaluated Dimebon ( latrepirdine ) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease.